An observational study in Neurodevelopmental Disorders and Congenital Cardiomyopathy, sponsored by University Hospital, Lille. Recruiting at 1 site in France. Open to participants aged 1 Day to 1 Year. Per ClinicalTrials.gov, last updated 2026-04-24.
Sponsored by University Hospital, Lille · Observational
Among 50 studies in Neurodevelopmental Disorders with a site in France — 31 open to participants now, 33 under way, 5 of them phase 3. Neurodevelopmental Disorders · France.
Among the 50 studies in Neurodevelopmental Disorders with a site in France, this one is the 21st largest by planned enrollment of the 25 observational ones, is one of 8 that started in 2022, is one of 25 observational ones, reaches primary completion later than 5 of the 32 other live ones, and was the 18th registered.
352 studies on the registry are indexed under Neurodevelopmental Disorders; 141 are open to participants now.
This study's planned enrollment of 50 is below the median of 200 across 133 observational studies indexed under Neurodevelopmental Disorders.
Browse Neurodevelopmental Disorders studies →31 of the 50 studies in Neurodevelopmental Disorders with a site in France are open now, in 12 countries. Each count lists the studies.
Of the 100 Neurodevelopmental Disorders studies recruiting now, 20 (20%) set no upper age limit and 76 (76%) stop at 75 or younger; 86 take children under 18; 31 take healthy volunteers.
This study: 1 Day to 1 Year · all sexes · no healthy volunteers.
The full table on the hub →50 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 8 started in 2022.
Median enrollment 132 across the 25 interventional studies, 200 across the 25 observational. Of the 12 that completed or were terminated, 0 (0%) have results posted.
7 of 50 have an industry lead sponsor. The 10 most frequent:
University Hospital, Lille is the lead sponsor of 631 studies on the registry; 142 are open to participants now.
University Hospital, Lille has 3 studies filed under Neurodevelopmental Disorders — fewer than ten, so there is no comparison to draw.
11 of the studies in Neurodevelopmental Disorders with a site in France that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06660394Phase 3Longboard PharmaceuticalsA Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) | 2026-12-31 |
| NCT07224581Phase 3GRIN Therapeutics, Inc.Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder | 2027-05 |
| NCT06908226Phase 3Longboard PharmaceuticalsA Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) | 2027-11-11 |
| NCT04952870University Hospital, LillePerinatal Covid-19 Infection, NO Pathway, and Minipuberty | 2026-11 |
| NCT05512637University Hospital, MontpellierScreening for Neurodevelopmental Disorders in Siblings of Children With Autism Diagnosed in Tertiary Centers | 2026-11 |
Among the 50 studies in Neurodevelopmental Disorders with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
Congenital cardiopathy are frequent malformations (1/100 birth). The progress of surgery permit a survival rate at the adult age of more than 90%. The long terms consequences must be taken in account and the nerodevelopmental disorders are in first place (intelectual deficiency, autism spectrum disorders, or attention disorders) and presents in 30 to 60% of the patients (Calmant, 2015). The impact can be important on the scolarity, the studies, the professional activity and finaly on the quality of life of the patients becomming adults.
The identification of the risk factors on surgery period should permit to propose the most adapted follow-up to the specifics needs of each patients.
On the scientific plans, the identification of early markers on brain dammage on EEG should permit to better apprehend the physiopathologic mecanisms involved.
Interest of early EEG on congenital cardiopathy surgery to predict the neurodevelopmental disorders occurence.
Congenital cardiopathy are frequent malformations (1/100 birth). The progress of surgery permit a survival rate at the adult age of more than 90%. The long terms consequences must be taken in account and the nerodevelopmental disorders are in first place (intelectual deficiency, autism spectrum disorders, or attention disorders) and presents in 30 to 60% of the patients (Calmant, 2015). The impact can be important on the scolarity, the studies, the professional activity and finaly on the quality of life of the patients becomming adults.
The identification of the risk factors on surgery period should permit to propose the most adapted follow-up to the specifics needs of each patients.
On the scientific plans, the identification of early markers on brain dammage on EEG should permit to better apprehend the physiopathologic mecanisms involved.
Children of less than 1 year suffering of congenital cardiopathy admitted for cardiac surgery on extracorporal circulation on the CHU of Lille.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Interest of pre and post surgery EEG on neurodevelopmental disorders
Evaluation of the interest of pre and post surgery EEG in the prediction of neurodevelopmental disorders on patients operated of congenital cardiopathy before the age of 1 year old.
Time frame: Age of patient : 24 Months
Association between orality disorders and neurodevelopmental disorders
Association between the presence of pre surgery and 1 year old orality disorder and occurence of neurodevelopmental disorders.
Time frame: Age of patient : 24 Months
Interest of post surgery EEG neurodevelopmental disorders at 24 months old
Evaluation of the interest of 24 months old post surgery EEG in the prediction of neurodevelopmental disorders on patients operated of congenital cardiopathy before the age of 1 year old, having a normal pre surgery EEG.
Time frame: Age of patient : 24 Months
Plan to share: No
Started Oct 2022 (actual). Primary completion is estimated for Oct 2026, 48 months after the start.
Of 67 non-industry observational studies under Neurodevelopmental Disorders, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 101. This study's planned 48 months is below that.
Counting every sponsor, half of 70 studies reached it within 59 months; a quarter within 32 and three quarters within 101.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Neurodevelopmental Disorders →